The portfolio maintains a sizable cost advantage over competitors, priced within the least expensive fee quintile among peers.
Invesco Biotechnology & Genome ETF PBE
Morningstar’s Analysis PBE
Will PBE outperform in future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
Parent Pillar
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings 47.4
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
---|---|---|---|
Biomarin Pharmaceutical Inc | 5.38 | 13.7 Mil | Healthcare |
Vertex Pharmaceuticals Inc | 5.20 | 13.2 Mil | Healthcare |
Regeneron Pharmaceuticals Inc | 5.20 | 13.2 Mil | Healthcare |
Gilead Sciences Inc | 5.15 | 13.1 Mil | Healthcare |
Amgen Inc | 5.09 | 12.9 Mil | Healthcare |
Illumina Inc | 5.08 | 12.9 Mil | Healthcare |
Incyte Corp | 4.98 | 12.7 Mil | Healthcare |
Neurocrine Biosciences Inc | 4.86 | 12.4 Mil | Healthcare |
Ionis Pharmaceuticals Inc | 3.26 | 8.3 Mil | Healthcare |
Halozyme Therapeutics Inc | 3.25 | 8.3 Mil | Healthcare |